TABLE 6

Differences between groups (first group minus second group) in percentages of children with anti-PRP antibody concentrations above the threshold and anti-PRP GMC ratios (first group to second group) approximately 5 years after booster vaccination (exploratory analyses; according-to-protocol cohorts for antibody persistence at 60 months after booster vaccination)a

Group comparisonDifference in proportions of children with anti-PRP antibody levels of ≥0.15 μg/ml (95% CI)Difference in proportions of children with anti-PRP antibody levels of ≥1 μg/ml (95% CI)Anti-PRP antibody GMC ratio (95% CI)
MenC-CRM vs MenC-TT0.71 (−2.97 to 4.59)9.47 (−2.34 to 20.99)0.96 (0.70–1.31)
MenC-CRM vs Hib-MenC + PHiD-CV−0.79 (−4.34 to 2.11)−17.69 (−27.93 to −7.31)0.54 (0.41–0.73)
MenC-CRM vs Hib-MenC + 7vCRM−0.79 (−4.34 to 2.06)−8.83 (−19.76 to 2.20)0.64 (0.47–0.87)
MenC-TT vs Hib-MenC + PHiD-CV−1.49 (−5.29 to 1.41)−27.15 (−37.34 to −16.49)0.56 (0.41–0.75)
MenC-TT vs Hib-MenC + 7vCRM−1.49 (−5.29 to 1.37)−18.29 (−29.18 to −6.99)0.65 (0.47–0.89)
  • a For differences, 95% CIs not including 0 were regarded as indicating significant potential differences between groups. For GMC ratios, 95% CIs not including 1 indicated significant potential differences. Bold type indicates comparisons for which the exploratory analysis suggests a potentially significant difference.